Medtronic (NYSE:MDT) said it’s begun distribution of its new insulin injection port, the i-port Advance.
The injection port is for diabetics who are on injection therapy, who easily scar or who have belonephobia, or fear of needles.
The bandage-like device, which is roughly the size of a quarter, is designed to be changed every 3 days, eliminating the need for needle sticks during those times.
Medtronic bought the technology from Patton Medical, according to a press release, and plans to expand distribution into market outside the U.S. "over the next several months." The i-port Advance has both CE Mark approval in the European Union and 510(k) clearance in the U.S., according to the release.
“Adding i-port Advance to our diabetes solutions portfolio puts us in a stronger position to support a broader group of people with diabetes – including those currently on injection therapy – with tools to help simplify diabetes management routines,” insulin delivery vice president and general manager Jeff Hubauer said in prepared remarks.
